文献速递神经肿瘤

原发性和复发性胶质母细胞瘤免疫生物学标志物分析

Analysis of immunobiologic markers in primary and recurrent glioblastoma.
PubMed 文献 · J Neurooncol · 2018-01-04

本研究用免疫组化检测原发性和复发性胶质母细胞瘤(GBM)样本中CD3、CD8、FoxP3、CD68、CD163、PD1、PDL1、CTLA4、CD70等免疫生物学标志物的表达,并用Aperio软件分析强阳性免疫反应程度,比较其与年龄、性别、MGMT启动子甲基化及ATRX、p53、IDH1突变状态的关系,同时用TCGA数据库RNA-seq作类似分析。结果显示免疫标志物与肿瘤分子特征的关系强于与原发/复发状态或年龄的关系。

要点

  • IDH1突变GBM的CD163和CD70表达显著降低,PD1、CTLA4和FoxP3呈降低趋势。
  • ATRX突变GBM的CD3免疫反应显著增高,p53突变GBM的CTLA4免疫反应显著增高。
  • MGMT甲基化肿瘤中CD8和CD68强阳性反应的比值比显著较低。

核心结论

  • 免疫生物学标志物与肿瘤分子特征的关系强于与原发/复发状态或年龄的关系。

研究设计与样本

  • 对人GBM样本进行免疫组化检测多种免疫生物学标志物,并用Aperio软件分析免疫反应性;另用TCGA数据库通过RNA-seq by expectation-maximization进行类似分析。

主要发现

  • IDH1突变GBM的CD163和CD70表达显著降低,PD1、CTLA4和FoxP3呈降低趋势。
  • ATRX突变GBM的CD3免疫反应显著增高,p53突变GBM的CTLA4免疫反应显著增高。
  • MGMT甲基化肿瘤中CD8和CD68强阳性反应的比值比显著较低。
  • 原发性和复发性GBM之间任何免疫标志物均无显著差异,各年龄区间之间免疫反应性也无显著变化。
  • TCGA分析证实了IDH1突变、p53突变和MGMT未甲基化肿瘤免疫谱差异的相关发现。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Glioblastoma (GBM) generates a varied immune response and understanding the immune microenvironment may lead to novel immunotherapy treatments modalities. The goal of this study was to evaluate the expression of immunologic markers of potential clinical significance in primary versus recurrent GBM and assess the relationship between these markers and molecular characteristics of GBM. Human GBM samples were evaluated and analyzed with immunohistochemistry for multiple immunobiologic markers (CD3, CD8, FoxP3, CD68, CD163, PD1, PDL1, CTLA4, CD70). Immunoreactivity was analyzed using Aperio software. Degree of strong positive immunoreactivity within the tumor was compared to patient and tumor characteristics including age, gender, MGMT promoter methylation status, and ATRX, p53, and IDH1 mutation status. Additionally, the TCGA database was used to perform similar analysis of these factors in GBM using RNA-seq by expectation-maximization. Using odds ratios, IDH1 mutated GBM had statistically significant decreased expression of CD163 and CD70 and a trend for decreased PD1, CTLA4, and Foxp3. ATRX-mutated GBMs exhibited statistically significant increased CD3 immunoreactivity, while those with p53 mutations were found to have significantly increased CTLA4 immunoreactivity. The odds of having strong CD8 and CD68 reactivity was significantly less in MGMT methylated tumors. No significant difference was identified in any immune marker between the primary and recurrent GBM, nor was a significant change in immunoreactivity identified among age intervals. TCGA analysis corroborated findings related to the differential immune profile of IDH1 mutant, p53 mutant, and MGMT unmethylated tumors. Immunobiologic markers have greater association with the molecular characteristics of the tumor than with primary/recurrent status or age.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Rahman M, Kresak J, Yang C, et al. Analysis of immunobiologic markers in primary and recurrent glioblastoma. J Neurooncol. 2018. PMID: 29302887. doi:10.1007/s11060-017-2732-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。